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Abstract
Background
Whether and how n-3 and n-6 polyunsaturated fatty acids (PUFAs) are related to type 2 dia-
betes (T2D) is debated. Objectively measured plasma PUFAs can help to clarify these
associations.
Methods and Findings
Plasma phospholipid PUFAs were measured by gas chromatography among 12,132 inci-
dent T2D cases and 15,919 subcohort participants in the European Prospective Investiga-
tion into Cancer and Nutrition (EPIC)-InterAct study across eight European countries.
Country-specific hazard ratios (HRs) were estimated using Prentice-weighted Cox regres-
sion and pooled by random-effects meta-analysis. We also systematically reviewed pub-
lished prospective studies on circulating PUFAs and T2D risk and pooled the quantitative
evidence for comparison with results from EPIC-InterAct. In EPIC-InterAct, among long-
chain n-3 PUFAs, α-linolenic acid (ALA) was inversely associated with T2D (HR per stan-
dard deviation [SD] 0.93; 95% CI 0.88–0.98), but eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA) were not significantly associated. Among n-6 PUFAs, linoleic acid
(LA) (0.80; 95% CI 0.77–0.83) and eicosadienoic acid (EDA) (0.89; 95% CI 0.85–0.94)
were inversely related, and arachidonic acid (AA) was not significantly associated, while
significant positive associations were observed with γ-linolenic acid (GLA), dihomo-GLA,
docosatetraenoic acid (DTA), and docosapentaenoic acid (n6-DPA), with HRs between
1.13 to 1.46 per SD. These findings from EPIC-InterAct were broadly similar to comparative
findings from summary estimates from up to nine studies including between 71 to 2,499
T2D cases. Limitations included potential residual confounding and the inability to distin-
guish between dietary and metabolic influences on plasma phospholipid PUFAs.
Conclusions
These large-scale findings suggest an important inverse association of circulating plant-ori-
gin n-3 PUFA (ALA) but no convincing association of marine-derived n3 PUFAs (EPA and
DHA) with T2D. Moreover, they highlight that the most abundant n6-PUFA (LA) is inversely
associated with T2D. The detection of associations with previously less well-investigated
PUFAs points to the importance of considering individual fatty acids rather than focusing on
fatty acid class.
Author Summary
WhyWas This Study Done?
• Most dietary guidelines recommend the consumption of polyunsaturated fatty acids for
cardiovascular health, but it is unclear whether or how n-3 and n-6 types of polyunsatu-
rated fatty acids are related to type 2 diabetes.
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• Health concerns have been raised previously about a diet high in linoleic acid (n-6 fatty
acid), but its association with type 2 diabetes is unclear.
• Major limitations in previous studies have included the error-prone subjective assess-
ment of the habitual consumption of polyunsaturated fatty acids when dietary intakes
were evaluated and a small number of type 2 diabetes cases (n = 71 to 673) when objec-
tive biomarkers of polyunsaturated fatty acids were measured.
What Did the Researchers Do and Find?
• Wemeasured circulating individual polyunsaturated fatty acids in the blood samples of
individuals within a large study from across eight countries of Europe among a reference
sample of 15,919 individuals as well as 12,132 individuals who subsequently developed
diabetes. Individuals were followed up for an average of approximately 10 y.
• We investigated the association between individual polyunsaturated fatty acids and the
risk of future type 2 diabetes using statistical analyses that accounted for factors that
could be potential alternative explanations for any observed associations.
• We found that higher levels of blood alpha-linolenic acid, a plant-origin n-3 fatty acid,
and n-6 linoleic acid, the most abundant type of polyunsaturated fatty acid, were associ-
ated with a lower risk of future type 2 diabetes. In contrast, higher levels of four other
minor individual n-6 fatty acids were associated with higher type 2 diabetes risk, while
the blood marine-origin n-3 fatty acids were not associated with future diabetes.
What Do These Findings Mean?
• Our findings show that it is important to consider individual circulating polyunsaturated
fatty acids for association with type 2 diabetes risk, rather than placing emphasis on the
class of circulating polyunsaturated fatty acids.
• We found that blood n-6 linoleic acid, the most abundant polyunsaturated fatty acid, is
inversely associated with type 2 diabetes.
• We found no evidence that blood total n-6 polyunsaturated fatty acids may elevate the
risk of type 2 diabetes, but several individual minor blood n-6 polyunsaturated fatty
acids were associated with increased type 2 diabetes risk, highlighting the importance of
polyunsaturated fatty acid metabolism in the development of type 2 diabetes.
Introduction
Recognition of the importance of dietary fat quality rather than a focus on total fat intake has
led to the promotion of dietary guidelines that encourage the consumption of polyunsaturated
fatty acids (PUFAs) for cardiometabolic health [1]. Dietary n-3 (omega-3) PUFAs, including
alpha-linolenic acid (ALA, 18:3n-3) from plant sources and eicosapentaenoic acid (EPA,
20:5n-3), docosahexaenoic acid (DHA, 22:6n-3), and docosapentaenoic acid (DPA, 22:5n-3)
from fish or seafood sources, are postulated to be beneficial for the prevention of type 2 diabe-
tes (T2D), but there is inconclusive evidence from both intervention and observational studies.
For instance, n-3 PUFA supplementation with EPA, DHA, or fish oil did not significantly
improve glycaemic or insulin markers in randomised trials among general populations or
Polyunsaturated Fatty Acids and Type 2 Diabetes
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among those with T2D [2,3]. Four separate meta-analyses of prospective studies of the associa-
tion between dietary long-chain n-3 PUFAs or fish intake, a major source of n-3 PUFAs, and
incidence of T2D reported heterogeneous findings with no association, higher risk, or lower
risk depending on geographical location [4–7]. Dietary n-6 (omega-6) PUFAs, although they
are about 5-fold to 7-fold more abundant in the Western diet than n-3 PUFAs [8,9], have not
been systematically examined, and the findings are inconsistent for association with T2D [10–
13]. There has also been an ongoing debate about whether dietary linoleic acid (LA; 18:2n6),
the most abundant n-6 PUFA, has adverse health effects and therefore whether its consump-
tion should be limited in the population [14–16].
To our knowledge, there is no trial assessing effects of long-term exposure to n-3 or n-6
PUFAs on incidence of T2D, while past evidence from observational studies is limited by accu-
racy in measurement of habitual PUFA consumption from self-report of dietary intake of
foods or supplements. Few studies have examined the associations of objectively measured cir-
culating blood PUFAs with incidence of T2D, with limited sample sizes and the inclusion of a
variable number of individual PUFAs [9,17–20].
We aimed to investigate the associations between objectively measured individual n-3 and
n-6 PUFAs in the plasma phospholipid fraction and incident T2D in the European Prospective
Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study [21]. As a second-
ary objective, to consider the totality of existing evidence, we also conducted a systematic litera-
ture review and performed a meta-analysis to compare with the findings from EPIC-InterAct.
Methods
Study Design and Population
The methods of the EPIC-InterAct project have previously been described in detail [21]. From
among 340,234 persons with 3.99 million person-years of follow-up (1991–2007) in the eight
countries of the EPIC study, we ascertained 12,403 T2D cases and selected a random subcohort
of 16,835 individuals with baseline plasma samples. After exclusions (n = 548 prevalent diabe-
tes; n = 133 uncertain diabetes status), the subcohort retained 16,154 individuals and included
778 individuals with incident T2D during follow-up (a feature of the case-cohort design) [21].
From the total 27,779 participants, we excluded 483 without blood fatty acid data, therefore
including 12,132 T2D cases and 15,919 subcohort participants in the analysis (with 755 inci-
dent cases included by design within the subcohort), with a mean follow-up of 9.8 y. All partici-
pants gave written informed consent, and the study was approved by the local ethics
committees in the participating countries and the Internal Review Board of the International
Agency for Research on Cancer.
T2D Case Adjudication
Incident T2D was ascertained until 31 December 2007 by reviewing multiple sources of evi-
dence, reported previously [21]: self-report, linkage to primary-care registers and secondary-
care registers, medication use, hospital admissions, and mortality data. No diabetes cases were
ascertained solely by self-report, and we sought further evidence for cases with information on
incident T2D from fewer than two independent sources.
Measurement of Plasma Phospholipid Fatty Acids
Fatty acids were profiled at the Medical Research Council Human Nutrition Research, Cam-
bridge, United Kingdom, by analysing plasma samples stored at baseline at −196°C (−150°C in
Denmark), a temperature at which fatty acids remain stable [22]. The assay methods were
Polyunsaturated Fatty Acids and Type 2 Diabetes
PLOSMedicine | DOI:10.1371/journal.pmed.1002094 July 19, 2016 4 / 17
described previously [23]. In short, the plasma phospholipid fraction was obtained using solid
phase extraction and hydrolysed and methylated, yielding fatty acid methyl esters (FAME),
which were separated by gas chromatography (J&W HP-88, 30 m length) equipped with flame
ionisation detection (7890N GC Agilent Technologies, United States). Samples from cases and
subcohort participants were processed in a random order by centre, and laboratory staff were
blinded to any participant characteristics. Fatty acids were identified by their retention times
compared with those of commercial standards and expressed as percent of total phospholipid
fatty acids (mol%). Among 27 fatty acids with relative concentrations above 0.05%, we identi-
fied 11 individual PUFAs (4 long-chain n-3 PUFAs and 7 n-6 PUFAs) (Fig 1, showing the bio-
synthesis pathways and major food sources). Human and equine plasma (Sera Laboratories
International, UK) were used as quality control samples and included in each batch [23]. The
coefficients of variation were less than 8% except for ALA (13%) and γ-linolenic acid (GLA,
21%) [23]. Using the fatty acid measurements, we calculated the sums of total n-3 PUFAs and
total n-6 PUFAs. We also estimated the ratios of PUFA variables in the context of biological
processes: 18:3n6 / 18:2n6 and 20:4n6 / 20:3n6, indicating estimated activity of Δ6 and Δ5 desa-
turase enzymes, respectively, catalysing the conversion of LA to GLA and of dihomo-γ-linole-
nic acid (DGLA) to arachidonic acid (AA); 20:3n6 / 18:2n6, indicating the conversion of LA to
DGLA; and ratio of total n-6 PUFAs / total n-3 PUFAs, for its clinical interest in balance
between the two major PUFA subclasses.
Measurement of Covariables at Baseline
Weight and height were measured by trained professionals to standardised protocols, and body
mass index (BMI) was calculated as weight divided by squared height (kg/m2). Lifestyle ques-
tionnaires were used to assess demographics, smoking status, medical history, and education
level. Physical activity was assessed by a validated questionnaire from which an ordered four-
category variable was derived. Glycated haemoglobin (HbA1c) was measured (SHL, Etten-
Leur, Netherlands) in the erythrocyte fraction from samples stored at −196°C (−80°C in
Umeå), using the Tosoh-G8 (Tosoh Bioscience, Japan).
Statistical Analysis
All analyses were performed using Stata, version 13 (Stata, College Station, Texas). We esti-
mated the association with incident T2D of each of the individual n-3 and n-6 PUFAs, total n-
3 PUFAs, total n-6 PUFAs, and predefined ratios of PUFA variables. Country-specific hazard
ratios (HRs) per standard deviation (SD; calculated in the subcohort) and 95% confidence
intervals (95% CI) were estimated using Prentice-weighted Cox regression [21], which allows
for over-representation of cases in a case-cohort design, and pooled using random-effects
meta-analysis. Heterogeneity between countries was expressed as I2 values [24]. We adjusted
for potential confounders as follows: Model 1 included age (as underlying timescale), study
centre, sex, physical activity index (inactive, moderately inactive, moderately active, or active),
smoking status (never, former, or current), education level (none, primary school, technical or
professional school, secondary school, or higher education) and BMI (continuous). Model 2
further adjusted for total energy intake (continuous), alcohol (none,>0–<6, 6–<12, 12–<24
and24 g/d), and the other potential dietary confounders unlikely to be major sources of
PUFAs: meat, fruits, vegetables, dairy products, and soft drinks (continuous). Model 3 addi-
tionally adjusted for possible dietary sources of PUFAs (fish and shellfish, nuts and seeds, vege-
table oil, olive oil, and margarine; continuous; Fig 1). In a secondary analysis, we also examined
the association of quintiles of each of the PUFA exposures with T2D.
Polyunsaturated Fatty Acids and Type 2 Diabetes
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In sensitivity analyses, using Model 3, we examined additional confounding or mediating
effects of plasma phospholipid saturated fatty acids (even-chain 14:0, 16:0, and 18:0; and odd-
chain 15:0 and 17:0; continuous), prevalent comorbidity (including myocardial infarction,
stroke, and cancer; yes/no for each), and baseline HbA1c. To minimise the possibility of reverse
causality, we repeated analyses after excluding 2,348 individuals with baseline HbA1c6.5%
(48 mmol/mol) and after excluding T2D cases (n = 1,048) occurring within 2 y after baseline.
Systematic Review and Meta-analysis of Published Studies
Our objective was to do a comparative meta-analysis of the existing evidence in order to pro-
vide a systematic comparison with EPIC-InterAct findings rather than providing a narrative
comparison. To compare the findings from EPIC-InterAct with the published literature, we
identified prospective studies published by 3 November 2015 that reported on the association
of circulating n-3 or n-6 PUFAs with T2D using PubMed (S1 Text for further details). We per-
formed a random effects meta-analysis of the association of circulating n-3 or n-6 PUFAs with
T2D from published studies identified as eligible from the literature review, using estimates
from a model with the greatest degree of adjustment for potential confounders. The overall
effect was estimated per study-specific SD [25] and meta-analysed by lipid fraction and across
lipid fractions for each fatty acid. Heterogeneity was assessed using Q and I2 statistics [24].
Publication bias was investigated using Egger’s and Begg’s tests.
Fig 1. Schematic showing the names of individual n-3 and n-6 PUFAsmeasured in EPIC-InterAct, their biosynthesis pathways, andmajor
dietary sources.
doi:10.1371/journal.pmed.1002094.g001
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Results
Table 1 summarises the baseline characteristics by case status, and S1 and S2 Tables show
characteristics by age, sex, BMI, and country. Among subcohort participants, PUFAs com-
prised a mean 42.7±2.1% of the total phospholipid fatty acids, of which n-6 PUFAs were more
abundant (35.9±2.9%) than n-3 PUFAs (6.7±2.0%). PUFAs with relatively high concentrations,
e.g.,>1%, were LA (22%), DGLA (3.1%), AA (9.2%), EPA (1.2%), and DHA (4.3%) (Figs 2
and 3).
The associations we observed did not change substantially by covariables examined (Model
1, 2, and 3) (Fig 2 and S7 Table). There was no evidence of an association between total n-3
PUFAs and T2D, but an inverse association was evident with ALA (18:3n3), with a per 1 SD
HR of 0.93 (95% CI 0.88–0.98; Model 3). There was no association with EPA (20:5n3) and
DHA (22:6n3), and a borderline inverse association with DPA (22:5n3). Heterogeneity of asso-
ciations by country appeared to be weak to moderate (I2 = 0% to 50%) (S1 Fig).
Sensitivity analyses were not markedly different for the majority of associations (S3 Table).
As an exception, n-3 PUFAs were found to be sensitive to additional adjustment, showing a
positive association of EPA with T2D [HR 1.09; 95% CI 1.04–1.14] when adjusted for odd-
chain saturated fatty acids and an inverse association of DHA (HR 0.92; 95% CI 0.87–0.98]
when adjusted for even-chain saturated fatty acids. Secondary analysis of quintiles of n-3
PUFAs showed similar overall patterns (S4 Table).
Associations with n-6 PUFAs are shown in Fig 3. LA (18:2n6) was strongly inversely associ-
ated with T2D (per 1 SD HR 0.80; [95% CI 0.77–0.83], Model 3]. AA (20:4n6) was not associ-
ated, while four of the individual n-6 PUFAs were positively associated with T2D: Model 3,
GLA (18:3n6) (HR 1.19; 95% CI 1.14–1.24], DGLA (20:3n6) (HR 1.46; 95% CI 1.34–1.59), doc-
osatetraenoic acid (DTA, 22:4n6) (HR 1.13; 95% CI 1.06–1.21), and n-6 DPA (22:5n6) (HR
1.14; 95% CI 1.05–1.24). In sensitivity analyses, results were similar, except adjustment for sat-
urated fatty acids altered findings for 22:4n6 and 22:5n6 to the null (S3 Table). Associations by
country are shown in S1 Fig. The findings using quintile distributions of n-6 PUFAs were con-
sistent (S4 Table). For instance, comparing the top and bottom quintiles, there was an inverse
association with T2D for LA (HR 0.54; 95% CI 0.47–0.61, p-trend< 0.001).
The ratio of GLA (18:3n6) to LA (18:2n6), representing estimated Δ6 desaturase activity,
was positively associated with T2D (HR 1.21, 95% CI 1.16–1.26; Model 3), while the ratio of
AA (20:4n6) to DGLA (20:3n6), representing Δ5 desaturase activity, was inversely associated
(HR 0.73; 95% CI 0.67–0.80). The ratio of DGLA to LA was positively associated with T2D
(HR 1.44; 95% CI 1.33–1.57), but there was no association of total n6 to n3 ratio with T2D (HR
0.98; 95% CI 0.93–1.04).
The flow diagram for the systematic literature search and study profiles is shown in S2 Fig
and S5 Table. The combined findings from the previously published evidence were based on
between 71 to a maximum of 2,499 T2D cases from between one to nine studies, depending on
individual fatty acids that were measured (Table 2). Compared with the findings in EPIC-Inter-
Act (12,131 T2D cases), the key differences were that each of circulating total n-6 PUFAs, LA,
eicosadienoic acid (EDA), DTA and n-6 DPA, as well as the estimated Δ6 desaturase activity,
were not significantly associated with T2D. There was no evidence of publication bias for any
fatty acid variables (pBegg’s and pEgger’s > 0.1), except for the 20:3n6/18:2n6 ratio (pBegg = 0.04
and pEgger = 0.003) for which exclusion of a potential outlying estimate retained the significant
positive association (S3 Fig). Despite differences in lipid fraction (e.g., plasma or erythrocyte
phospholipids or total sera), laboratory setting, and population characteristics, there was little
heterogeneity for ALA and GLA (I2 = 0) and moderate heterogeneity for major individual
PUFAs (EPA, DPA, DHA, and LA) (I2 = 30% to 53%), but substantial heterogeneity for total
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n-3, total n-6, AA, and the other minor PUFAs. The observed heterogeneity was not explained
to a significant degree by lipid fraction in metaregression analysis, except for total n-3 and AA
where I2 as the measure of heterogeneity became 0.0% after adjustment for lipid fractions (S6
Table).
Table 1. The distribution of sociodemographic and dietary factors at baseline by future case and noncase status: EPIC-InterAct study.
Noncases Cases
n = 15,164 n = 12,132
Mean / % n / SD Mean / % n / SD
Age (y) 52.2 9.2 55.6 7.7
BMI (kg/m2) 25.8 4.1 29.7 4.7
Sex
Men 37.1 5,629 49.7 6,030
Women 62.9 9,535 50.3 6,102
Education Level
None 7.3 3,525 9.7 3,615
Primary 32.0 5,016 41.1 3,918
Technical or professional 22.7 3,388 22.9 2,434
Secondary 15.4 3,028 10.9 1,992
Higher education 20.7 13.0
Physical Activity 1,101 1,171
Inactive 23.2 4,851 29.8 4,989
Moderately inactive 33.1 3,446 32.3 2,783
Moderately active 22.3 2,336 20.1 1,323
Active 20.0 3,141 16.4 1,574
Smoking Status
Never 46.7 7,077 40.3 4,895
Former 26.7 4,050 30.8 3,739
Current 25.5 3,860 27.6 3,344
Alcohol Consumption
None 16.0 2,432 18.3 2,223
>0–<6 g/d 33.7 5,117 32.3 3,924
6–<12 g/d 15.7 2,378 14.0 1,701
12–<24 g/d 16.1 2,439 14.7 1,788
24 g/d 18.1 2,751 20.0 2,426
Total Energy Intake (kcal/d) 2,136 631 2,175 671
Median IQR Median IQR
Intake (g/d) of:
Meat 73.8 (46.1,107.9) 83.8 (53.4,120.9)
Fruit and vegetables 369.5 (236.4,544.6) 355.0 (223.0,537.3)
Soft drinks 3.3 (0,64.7) 9.8 (0,92.4)
Dairy 287.7 (168.0,455.7) 281.1 (159.5,464.7)
Fish and shellfish 28.9 (14.8,51.2) 32.1 (16.1,55.2)
Nuts and seeds 0 (0,1.3) 0 (0,0.4)
Vegetable oil 5.5 (1.2,20.4) 4.9 (0.5,19.8)
Olive oil 0.02 (0,13.9) 0 (0,10.5)
Margarine 5.3 (0.08,21.8) 7.4 (0.09,25.0)
BMI, body mass index; IQR, interquartile range; SD, standard deviation.
doi:10.1371/journal.pmed.1002094.t001
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Discussion
EPIC-InterAct provides the largest and most extensive evaluation to date of the association
between 11 individual plasma phospholipid n-3 and n-6 PUFAs and incident T2D. These find-
ings indicate that there is no significant association between total n-3 PUFAs and T2D, but
that the plant-derived n-3 PUFA, ALA, is robustly inversely associated with T2D incidence. In
contrast, the largely marine-derived n-3 PUFAs were not associated, except for a modest
inverse association of DPA with T2D. Total plasma phospholipid n-6 PUFAs were inversely
associated, largely driven by the most abundant circulating PUFA, LA. Our findings also high-
light that four n-6 PUFAs (GLA, DGLA, DTA, and n-6DPA) were associated with higher T2D
incidence, while AA (20:4n6) was not associated with T2D. There was no association of the
total n6-to-n3 PUFA ratio, but estimated Δ6 desaturase activity was positively—and Δ5 desa-
turase activity inversely—associated with T2D.
Fig 2. HRs of T2D and 95%CIs per 1 SD increase in total and individual n-3 PUFAs (ALA, EPA, DPA, and DHA): EPIC-InterAct study.Model 1:
displayed as diamonds. Age as underlying time variable, and adjusted for centre, sex, physical activity (inactive, moderately inactive, moderately active,
or active), smoking (never, former, or current), education level (none, primary school, technical or professional school, secondary school, or higher
education), and BMI (continuous, kg/m2). Model 2: displayed as circles. Adjusted as in Model 1 + total energy intake (continuous, kcal/d), alcohol (none,
>0–<6, 6–<12, 12–<24 and24 g/d), and (continuous, g/d intake of) meat, fruit and vegetables, dairy products, and soft drinks. Model 3: displayed as
squares. Adjusted as in Model 2 + (continuous, g/d intake of) fish and shellfish, nuts and seeds, vegetable oil, olive oil, and margarine.
doi:10.1371/journal.pmed.1002094.g002
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Findings in Context: n-3 Fatty Acids
The overall null associations of circulating EPA and DHA with T2D in EPIC-InterAct are con-
sistent with our concurrent comparative meta-analysis of the published literature. Moreover,
our findings for circulating EPA and DHA are consistent with the lack of evidence of associa-
tion between dietary EPA+DHA intakes and T2D risk in prospective cohorts [6] or of net ben-
efit or harm of marine-origin n-3 supplementation on glycaemia or insulin sensitivity in
randomised trials [2,3,26]. However, our sensitivity analyses showed that the null findings for
EPA and DHA should be interpreted with caution because there was a positive association of
T2D with EPA after further adjustment for the odd-chain saturated fatty acids (15:0 and 17:0)
and, conversely, an inverse association with DHA after adjustment for even-chain saturated
fatty acids (sum of 14:0, 16:0, and 18:0). This indicates that the observed findings may be influ-
enced by complex inter-relationships and metabolic effects of different fatty acids [27], but the
totality of current evidence does not support benefits of EPA or DHA for T2D prevention.
Fig 3. HRs of T2D and 95%CIs per 1 SD increase in total and individual n-6 PUFAs (LA, GLA, EDA, DGLA, AA, DTA, and n-6 DPA): EPIC-InterAct
study.Model 1: displayed as diamonds. Age as underlying time variable, and adjusted for centre, sex, physical activity (inactive, moderately inactive,
moderately active, or active), smoking (never, former, or current), education level (none, primary school, technical or professional school, secondary
school, or higher education), and BMI (continuous, kg/m2). Model 2: displayed as circles. Adjusted as in Model 1 + total energy intake (continuous, kcal/
d), alcohol (none, >0–<6, 6–<12, 12–<24 and24 g/d), and (continuous, g/d intake of) meat, fruit and vegetables, dairy products, and soft drinks. Model
3: Displayed as squares. Adjusted as in Model 2 + (continuous, g/d intake of) fish and shellfish, nuts and seeds, vegetable oil, olive oil, and margarine.
doi:10.1371/journal.pmed.1002094.g003
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On the other hand, we found a modest inverse association between DPA and T2D in EPI-
C-InterAct as well as in our comparative meta-analysis, though it has been less well investi-
gated previously [6,28]. n-3 DPA is an intermediate between EPA and DHA and appears to
have unique biological functions—for example, having a greater potency than EPA and DHA
as a precursor of eicosanoids [28]—but little is known of DPA’s glycaemic effects [29,30]. In
genome-wide association analyses, gene variants associated with circulating n-3 PUFA were
found to explain 11.4% of the variance of DPA, much higher than that for EPA or DHA (<1%)
[31], highlighting that DPA levels are related to fatty acid metabolism. Our current findings
suggest that there may be a potential beneficial (inverse) association between DPA and T2D,
but further biochemical and clinical research is needed to examine a causal role of DPA on gly-
caemic outcomes and regulation of DPA synthesis.
Our findings provide convincing evidence for an inverse association between the plant
food-based circulating ALA and T2D. This is in line with supportive evidence from rando-
mised trials that ALA or flaxseed oil (rich in ALA) intervention could improve glucose homeo-
stasis [32–35] and also in line with prior weak evidence of dietary ALA showing nonsignificant
Table 2. Results for associations of circulating n-3 and n-6 PUFAs and fatty acid ratios with incidence of T2D: EPIC-InterAct study and compara-
tive meta-analysis of the published prospective studies*.
HR (95% CI)
EPIC-InterAct*
n Cases HR (95% CI) Comparative Meta-
analysis*
n
Cases
n
Studies
I2 P-
heterogeneity
n-3 Polyunsaturated Fatty Acids 0.98 (0.93–1.03) 12,131 0.95 (0.84–1.06) 1,667 5 63.2 0.03
α-Linolenic acid, ALA (18:3n3) 0.93 (0.88–0.98) 12,131 0.96 (0.92–0.99) 2,499 9 0 0.62
Eicosapentaenoic acid, EPA
(20:5n3)
1.05 (0.99–1.10) 12,131 0.96 (0.90–1.01) 2,499 9 38.7 0.11
Docosapentaenoic acid, DPA
(22:5n3)
0.95 (0.91–1.00) 12,131 0.92 (0.86–0.99) 2,043 7 38.2 0.14
Docosahexaenoic acid, DHA
(22:6n3)
0.95 (0.90–1.01) 12,131 0.97 (0.91–1.03) 2,499 9 52.6 0.03
n-6 Polyunsaturated Fatty Acids 0.87 (0.83–0.91) 12,131 0.89 (0.77–1.02) 1,667 5 73.9 <0.001
Linoleic acid, LA(18:2n6) 0.80 (0.77–0.83) 12,131 0.86 (0.77–0.95) 1,907 8 50.1 0.05
γ-Linolenic acid, GLA (18:3n6) 1.19 (1.14–1.24) 12,131 1.19 (1.08–1.30) 1,195 4 0 0.43
Eicosadienoic acid, EDA (20:2n6) 0.89 (0.85–0.94) 12,131 0.82 (0.54–1.23) 872 2 86.3 0.01
Dihomo-γ-linolenic acid, DGLA
(20:3n6)
1.46 (1.34–1.59) 12,131 1.30 (1.11–1.52) 1,714 6 77.0 <0.001
Arachidonic acid, AA (20:4n6) 1.02 (0.98–1.06) 12,131 1.02 (0.91–1.16) 1,873 7 71.4 <0.001
Docosatetraenoic acid, DTA
(22:4n6)
1.13 (1.06–1.21) 12,131 1.15 (0.94–1.41) 903 3 60.2 0.08
Docosapentaenoic acid, n6-DPA
(22:5n6)
1.14 (1.05–1.24) 12,131 1.22 (0.97–1.53) 71 1
Fatty Acid Ratios
Ratio: 18:3n6 / 18:2n6 (Δ6
desaturase)
1.21 (1.16–1.26) 12,131 1.21 (0.97–1.50) 226 2 86.4 <0.001
Ratio: 20:4n6 / 20:3n6 (Δ5
desaturase)
0.73 (0.67–0.80) 12,131 0.75 (0.70–0.80) 948 5 0 0.93
Ratio: 20:3n6/ 18:2n6 (DGLA to LA
ratio)
1.46 (1.34–1.59) 12,131 1.52 (1.33–1.73) 722 4 40.9 0.17
Ratio: n6/n3 0.98 (0.93–1.04) 12,131 0.93 (0.80–1.07) 364 1
* HRs for EPIC-InterAct are per 1 SD of each fatty acid using estimates from Model 3 (see methods). For the comparative literature-based meta-analysis,
the HRs are per 1 SD (study specific) of each fatty acid, derived from random-effects meta-analysis based on the model most adjusted for potential
confounders in each study. Results for the comparative literature-based meta-analysis were derived from one to nine prospective cohort, case-cohort, or
nested case-control studies (S5 Table).
doi:10.1371/journal.pmed.1002094.t002
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inverse association with T2D with relative risk 0.93 (95% CI 0.83–1.04) [6]. Conversion of
ALA (an essential fatty acid from the diet) to long-chain n-3 PUFAs is not likely to explain the
observation, because the conversion is small (0.2%–8% of ALA) [36] and because neither EPA
nor DHA was associated with T2D. The precise mechanisms of how ALA may influence diabe-
tes risk are unknown, but there is evidence suggesting that ALA may induce insulin secretion
through direct actions on G-protein receptors expressed in pancreatic β-cells and through
stimulating enteroendocrine L-cells, as well as by enhancing insulin sensitivity through hepatic
insulin-like growth factor-1 (IGF-1) related pathways [37].
Findings in Context: n-6 Fatty Acids
EPIC-InterAct findings provide convincing evidence for a strong inverse association between
circulating LA (18:2n6), the most abundant of all PUFAs, and T2D, with a 20% lower incidence
per SD higher LA level. A prevailing concern relates to LA being the metabolic precursor to
proinflammatory metabolites, particularly AA-derived eicosanoids, though the deleterious
effects are not definitively proven and may depend on a complex interplay of metabolic factors
[15,38]. Our observation in EPIC-InterAct that AA (20:4n6) is not associated—but intermedi-
ate metabolites GLA (18:3n6), DGLA (20:3n6), and estimated Δ6 desaturase activity are
adversely (positively) associated—is in line with a previous Mendelian randomisation study
suggesting a potential causal adverse association of estimated Δ6 desaturase activity (desatura-
tion of LA! GLA) with T2D, but not for Δ5 desaturase activity (DGLA!AA) [9]. Despite the
causal inference for estimated Δ6 desaturase activity on T2D risk, the biological mechanisms
are speculated but not yet proven [9].
There is little other evidence to compare the EPIC-InterAct findings of the three relatively
low-abundance n-6 PUFAs that were associated with lower risk (EDA, 20:2n6) or higher risk
(DTA, 22:4n6, and n6-DPA, 22:5n6) of T2D.
Strengths and Limitations
Key strengths of EPIC-InterAct are its large sample size, prospective study design, and long fol-
low-up. Moreover, the inclusion of EPIC-InterAct populations from eight European countries
with diverse dietary intakes, comprehensive T2D case ascertainment and verification, the
adjustment for many relevant potential confounders, and a series of sensitivity analyses
enabled us to report robust findings, though we cannot rule out residual confounding. Our
meta-analysis of other available studies enabled us to provide a systematic comparison with
EPIC-InterAct findings and to place them in context of the wider evidence. We did not seek to
provide pooled summary estimates that included findings from EPIC-InterAct as its large size
with n = 12,132 T2D cases far outweighs the incident cases contributed by the other studies
(ranging between 71 to 2,499 cases).
Several limitations merit attention. Our measurements of PUFAs might have involved
misclassification because of measurement only at baseline and long-term storage of plasma
samples. However, samples stored at −196°C are likely to be stable over time [22], and any
errors were likely to be at random with respect to case status. We could only examine relative
and not absolute concentrations of fatty acids, but this is a valid approach adopted commonly
in epidemiological research and tends to provide better interpretation of metabolic inter-rela-
tionships [22]. Plasma phospholipid PUFAs may reflect both dietary and metabolic influ-
ences, but we could not distinguish these. We were unable to examine correlations between
dietary and circulating individual PUFAs since in EPIC-InterAct we did not have dietary data
on individual PUFAs. However, in general the correlations with circulating levels are low to
modest because of measurement error issues of self-report and the linkage with food
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composition databases, as well as the different time frames of assessment between recall of
habitual intake in a food frequency questionnaire (FFQ) versus circulating blood fatty acids.
In contrast, there is evidence from dietary intervention trials that essential PUFAs in the
blood (n-3 PUFA ALA, and n-6 PUFA LA) reflect dietary intakes of PUFAs [22]. However,
we also need to note that circulating PUFAs may be exchanged across tissues and metabolised
to diverse molecules [28]. Our clinical case ascertainment could be limited by potential mis-
classification due to false positive or negative diagnoses. However, we minimised false posi-
tives by applying rigorous verification criteria, while potential false negatives due to
undiagnosed incident diabetes can be assumed to be nondifferential with regard to the expo-
sure and hence any potential bias would be unlikely to alter our conclusions based on a rela-
tive scale (HR) in our analysis. Being based in European populations, our findings may have
limited generalisability to other populations. Our comparative meta-analysis may be limited
by using risk estimates per study-specific SD because the biological meaning of one SD may
vary by studies. Thus, the estimates should be interpreted cautiously as risks per relative rank-
ing on average, though the per-SD estimates are also advantageous given differences in lipid
fractions, the number of fatty acids assessed, and laboratory methods. These differences in
PUFA measurements across different cohorts point to the advantage of the standardised labo-
ratory methods for measuring PUFA in EPIC-InterAct.
Implications
The lack of association of circulating EPA and DHA with T2D in EPIC-InterAct differs from
the evidence for their inverse association with cardiovascular disease [39]. Whether or not die-
tary long-chain n-3 PUFAs reduce cardiovascular events is currently unresolved [39,40], but
their overall beneficial effects on lipids (e.g., lowering of triglycerides), together with proposed
anti-inflammatory, antiarrhythmic, and antithrombotic effects, and effects on improved endo-
thelial function and blood pressure are plausible mechanisms [26]. In contrast, our current
report of a lack of association between circulating EPA or DHA and incident T2D is supported
by findings from randomised trials that found no evidence of net benefit or harm of long-chain
n-3 supplementation on glycaemia or insulin sensitivity [2,3,26]. Therefore, our current find-
ings advance scientific understanding of the possible differential links between circulating n-3
fatty acids and different health endpoints. Moreover, our findings for DPA and for ALA, both
being inversely associated with incident T2D, deserve further follow-up to understand mecha-
nisms and causality.
There has been an ongoing debate about the pros and cons of a diet high in the n6-PUFA
LA (18:2n6), mainly for cardiovascular health [14,39,41]. This is important to resolve as LA is
ubiquitous, being present in a wide variety of foods [38]. The strong evidence that dietary LA
influences circulating LA has been reviewed previously [22], and in that context our finding of
the inverse association between circulating LA and T2D incidence may have potential implica-
tions for the development of dietary advice. However, future work is warranted to build a body
of evidence using diverse study designs that compare dietary LA, circulating LA, and their
metabolites for the prevention of T2D.
Conclusion
We provide robust large-scale evidence that circulating plasma phospholipid n-3 PUFA ALA
and n-6 PUFA LA concentrations are associated with lower incidence of T2D. In contrast
four n-6 PUFAs (GLA, DGLA, DTA, and n-6DPA) are associated with higher T2D incidence
in EPIC-InterAct. These findings (i) highlight that it is important to consider individual
PUFAs rather than focusing on overall circulating n-3 or n-6 PUFA groups; (ii) provide
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robust evidence that circulating LA, the most abundant PUFA, is inversely associated with
T2D; and (iii) meaningfully advance our understanding that some fatty acids (EPA and
DHA) may be related differently with T2D or cardiovascular disease, while stimulating a sci-
entific debate about the potential role of other, previously less well studied individual fatty
acids.
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